Blastic plasmacytoid dendritic cell neoplasia – Diagnostics – Overview of Information and Clinical Research

Blastic plasmacytoid dendritic cell neoplasm is a rare and aggressive blood cancer that often first appears as skin lesions, making early and accurate diagnosis crucial for starting the right treatment as soon as possible.

Introduction: Who Should Undergo Diagnostics

People who develop unusual skin changes should consider seeking medical evaluation, particularly if they notice nodules, tumors, purple or red patches, or bruise-like marks that appear without an obvious cause. These skin abnormalities are present in most people with blastic plasmacytoid dendritic cell neoplasm, occurring in approximately 61% to 90% of cases. While the condition can affect anyone at any age, including infants and children, it is far more common in older adults, especially those between 60 and 80 years of age.^[4]^[1]

Because blastic plasmacytoid dendritic cell neoplasm presents with symptoms that can easily be confused with other conditions, maintaining a low threshold for seeking medical attention and requesting a biopsy (a procedure where a small tissue sample is removed for examination) is essential. The disease is uncommon enough that a general oncologist in a community setting may never encounter a case, which can lead to initial misdiagnosis or delays in proper identification.^[2]

Individuals should be particularly vigilant if skin lesions are accompanied by other concerning symptoms such as persistent fatigue, unexplained weight loss, swollen lymph nodes (especially in the neck), or an enlarged liver or spleen. These additional signs may indicate that the disease has spread beyond the skin and requires urgent medical evaluation. The combination of skin abnormalities with these systemic symptoms warrants immediate attention from a healthcare provider who can order appropriate diagnostic tests.^[1]

People with a history of other blood disorders should also be aware that blastic plasmacytoid dendritic cell neoplasm can occur alongside or following other conditions. About 10% to 20% of individuals diagnosed with this disease have previously had myelodysplastic syndrome (a group of disorders where the bone marrow doesn’t produce enough healthy blood cells), chronic myeloid leukemia, chronic myelomonocytic leukemia, or acute myeloid leukemia. If you have been treated for any of these conditions and develop new symptoms, especially skin lesions, it’s important to inform your doctor promptly.^[1]

⚠️ Important

Because blastic plasmacytoid dendritic cell neoplasm can be mistaken for benign skin conditions or other types of cancer, it’s crucial not to dismiss unusual skin changes as harmless. Early diagnosis significantly impacts treatment options and outcomes. If you notice persistent skin nodules, purple patches, or lesions that don’t heal, especially combined with fatigue or weight loss, seek medical evaluation promptly and don’t hesitate to request a biopsy if your healthcare provider hasn’t already suggested one.

Classic Diagnostic Methods

The diagnostic process for blastic plasmacytoid dendritic cell neoplasm begins with a thorough physical examination and medical history review. Healthcare providers will carefully examine any skin lesions, noting their location, size, color, and characteristics. They will also check for enlarged lymph nodes, liver, or spleen by feeling these areas during the physical exam. The most common skin presentation includes nodules, tumors, red or purple raised bumps, bruise-like patches, and sometimes open sores that typically appear on the head, face, and upper body, though they can develop anywhere.^[4]

A skin biopsy is essential for confirming the diagnosis. During this procedure, doctors remove a sample of the abnormal skin tissue, which is then examined under a microscope by a pathologist. The pathologist looks for specific patterns of cells infiltrating the skin tissue. However, simply looking at the cells under a microscope isn’t enough to make a definitive diagnosis of blastic plasmacytoid dendritic cell neoplasm, because the cells can resemble those seen in other blood cancers or lymphomas.^[7]

Immunohistochemistry is a specialized laboratory technique that is absolutely necessary to confirm the diagnosis. This method uses specific antibodies to detect particular proteins on the surface of the cancer cells. For blastic plasmacytoid dendritic cell neoplasm to be diagnosed, the cells must test positive for a specific pattern of markers. The disease is most easily identified by the presence of CD4, CD56, and CD123 markers, while lacking markers typically found on other types of blood cells. CD123, in particular, is nearly universally and highly expressed in this disease and is considered a defining characteristic that pathologists must see to make the diagnosis.^[7]^[13]

It’s important to understand that not all patients will show the exact same pattern of markers. Some individuals may have variable expression of CD4, CD56, or other plasmacytoid markers (proteins typically found on plasmacytoid dendritic cells), which can make it more difficult to distinguish blastic plasmacytoid dendritic cell neoplasm from other blood cancers. This variability is why having an experienced pathologist and using comprehensive testing panels is so crucial.^[7]

Blood tests provide important information about how the disease is affecting the body. A complete blood count can reveal abnormalities such as low red blood cell counts (anemia), low platelet counts (thrombocytopenia), or low white blood cell counts (leukopenia). In some cases, malignant plasmacytoid dendritic cells may be visible circulating in the blood. When doctors examine a blood sample under a microscope, they may see blast cells with large, round, and slightly irregular nuclei, with cytoplasm that appears grayish-blue without granules or rod-shaped structures called Auer rods.^[14]

A bone marrow biopsy is a critical diagnostic procedure that helps determine whether the disease has spread to the bone marrow. This test involves removing a small sample of bone marrow, usually from the hip bone, using a special needle. The sample is then examined under a microscope and tested with immunohistochemistry. In one example case, the bone marrow showed 40% blast cells and was found to be 80% cellular with an interstitial infiltrate pattern. In general, bone marrow involvement is detected in approximately 65% of cases at the time of diagnosis.^[14]^[4]

Flow cytometry is another laboratory technique used on blood or bone marrow samples. This method allows doctors to identify and count cells based on their surface markers more rapidly and precisely than microscopy alone. For blastic plasmacytoid dendritic cell neoplasm, flow cytometry typically shows cells that are positive for CD4, CD56, CD123, and sometimes CD34, while being negative for T-cell and B-cell markers. This pattern helps distinguish the disease from lymphomas and other leukemias.^[14]

Chromosomal and genetic testing is performed to look for abnormalities in the cancer cells’ DNA. Cytogenetics is a technique that examines the chromosomes within cells to detect changes in their number or structure. Chromosomal abnormalities are frequently found in blastic plasmacytoid dendritic cell neoplasm, although no single specific chromosomal change defines the disease. The mutational landscape (the pattern of genetic mutations present in the cancer) is being actively studied, though researchers have not yet identified an obvious molecular target that could be used for specialized treatments.^[7]

Imaging studies may be ordered to assess the extent of disease spread. These can include CT scans (computed tomography), which use X-rays to create detailed cross-sectional images of the body, or PET scans (positron emission tomography), which show areas of high metabolic activity that might indicate cancer. These imaging tests help doctors determine whether the disease has affected internal organs such as the lymph nodes, liver, spleen, or other tissues.^[4]

A lumbar puncture, also called a spinal tap, may be performed to check whether the disease has spread to the central nervous system. During this procedure, a needle is inserted into the lower back to collect a small sample of cerebrospinal fluid (the fluid that surrounds the brain and spinal cord). The fluid is then examined for the presence of malignant cells. Central nervous system involvement has been detected in 47% of childhood cases, though it appears to be less commonly detected in adult cases. In one example case, the lumbar puncture showed no abnormal increase in cells and no central nervous system involvement.^[3]^[14]

The process of distinguishing blastic plasmacytoid dendritic cell neoplasm from other conditions can be challenging. The disease must be differentiated from benign skin lesions, other types of lymphoma, acute myeloid leukemia with skin involvement (called leukemia cutis), and various other blood cancers. This is why a comprehensive approach using multiple diagnostic methods—including tissue biopsy, immunohistochemistry, flow cytometry, bone marrow examination, and sometimes genetic testing—is essential for reaching an accurate diagnosis.^[7]

Diagnostics for Clinical Trial Qualification

When individuals with blastic plasmacytoid dendritic cell neoplasm are being considered for enrollment in clinical trials, they typically undergo a standardized set of diagnostic tests. These tests serve multiple purposes: they confirm the diagnosis beyond any doubt, they establish baseline measurements that will be compared to future tests to see if treatment is working, and they ensure that patients meet the specific criteria required for the particular study they’re joining.

The cornerstone of clinical trial qualification remains immunohistochemical confirmation of the diagnosis. Clinical trials require definitive proof that the participant has blastic plasmacytoid dendritic cell neoplasm and not another condition. This means that tissue samples must clearly demonstrate the characteristic pattern of markers, particularly the expression of CD123, CD4, and CD56, along with the absence of markers for other cell lineages. The testing must show that the cells are negative for MPO (myeloperoxidase, an enzyme found in certain white blood cells) and other lineage markers.^[7]

Bone marrow evaluation is typically required for clinical trial enrollment. Participants must have a bone marrow biopsy and aspiration performed to determine the percentage of blast cells present and to assess overall bone marrow function. This information helps researchers categorize patients by disease stage and severity, which can influence which treatment arm of a trial they’re assigned to or whether they’re eligible at all. The bone marrow findings also serve as a baseline for measuring response to experimental treatments.^[14]

Complete blood counts with differential are standard baseline tests for clinical trials. These tests measure red blood cells, white blood cells, platelets, and the different types of white blood cells present. The results provide information about how the disease is affecting normal blood cell production and help identify patients who may have leukemic spread of the disease (malignant cells circulating in the blood). In clinical trials, having more than 2% malignant cells in the blood has been noted in approximately 40% of cases at presentation.^[4]

Comprehensive metabolic panels and organ function tests are required to ensure that participants can safely tolerate the experimental treatment. These blood tests assess kidney function, liver function, electrolyte levels, and other metabolic parameters. Clinical trials have specific requirements about how well these organs must be functioning, and participants who have significant organ damage may not be eligible for certain studies, particularly those involving intensive therapies.

Imaging studies are typically required as part of the baseline assessment for clinical trial enrollment. These may include CT scans or PET scans to document the extent of disease involvement in lymph nodes, spleen, liver, or other organs. Having detailed imaging at the start of the trial provides a reference point for later scans that will be used to determine whether the experimental treatment is shrinking tumors or slowing disease progression.

Central nervous system evaluation may be required, particularly for trials involving intensive therapies or those specifically studying treatments for patients with central nervous system involvement. This typically involves a lumbar puncture to collect and test cerebrospinal fluid for malignant cells. Some clinical trials may exclude patients with central nervous system disease, while others may specifically enroll this patient population.^[3]

Performance status assessment is a standard requirement for clinical trial eligibility. Healthcare providers use scales such as the ECOG performance status (Eastern Cooperative Oncology Group scale) to rate how well patients can carry out daily activities. This scale ranges from 0 (fully active, able to carry on all activities without restriction) to 4 (completely disabled, cannot carry out any self-care). Most clinical trials have specific performance status requirements, often requiring that participants be ECOG 0, 1, or 2, meaning they can care for themselves even if they need some assistance with strenuous activities.^[14]

Some clinical trials, particularly those testing targeted therapies, may require additional specialized testing. For example, trials testing drugs that target CD123, such as tagraxofusp-erzs, require confirmation that the patient’s cancer cells express CD123 at high levels. Since CD123 is nearly universally expressed in blastic plasmacytoid dendritic cell neoplasm, most patients meet this criterion, but verification through immunohistochemistry or flow cytometry is still necessary.^[13]

Genetic and molecular testing may be incorporated into clinical trial protocols, particularly in research studies aimed at understanding the disease better or identifying new therapeutic targets. While no specific genetic mutation is required for diagnosis, many trials collect samples for research purposes to analyze the mutational landscape of the disease. This research may help future patients by identifying patterns that predict which treatments will work best for which individuals.

⚠️ Important

If you’re interested in participating in a clinical trial, talk to your healthcare team about which trials might be appropriate for your situation. Each trial has specific eligibility criteria, and some of the diagnostic tests required for enrollment may differ from those done as part of standard care. Your medical team can help coordinate the necessary testing and determine whether you meet the requirements for specific studies. Clinical trials offer access to novel treatments that may not yet be widely available and contribute to advancing knowledge about this rare disease.

Prognosis and Survival Rate

Prognosis

The prognosis for individuals with blastic plasmacytoid dendritic cell neoplasm is generally challenging, though outcomes can vary based on several factors. This is an aggressive disease, and despite initial responses to treatment, relapse is unfortunately common. The disease often returns in a form that is more resistant to treatment than it was initially. In some cases, blastic plasmacytoid dendritic cell neoplasm can occur alongside myelodysplastic syndrome or chronic myelomonocytic leukemia, or it may transform into acute myeloid leukemia, which further complicates the prognosis.^[4]

Factors that influence disease progression include the patient’s age, overall health, performance status, and whether they are eligible for intensive treatments. Younger patients and those with fewer other medical conditions generally have better outcomes. The extent of disease at diagnosis also plays a role, with more widespread involvement of organs and the central nervous system typically associated with greater challenges in achieving long-term control of the disease.^[1]

For patients who are able to undergo allogeneic hematopoietic stem cell transplantation during their first remission, the outlook is more hopeful compared to those who cannot receive this treatment. However, even with transplantation, relapse rates remain concerning, ranging from 30% to 40%. Despite this risk, transplantation offers the best chance at prolonged remission and possible cure for those who are eligible for this intensive procedure.^[7]

It’s worth noting that in children and young adults, the disease appears to behave somewhat differently than in older adults. Pediatric cases are believed to be clinically less aggressive in some ways, though children often present with more widespread disease. Unlike adults who almost always proceed to transplantation if they’re eligible, many children can be cured with intensive chemotherapy regimens similar to those used for high-risk acute lymphoblastic leukemia. Transplantation is recommended for children with high-risk features or those whose disease returns after initial treatment.^[3]

Survival Rate

Historical survival rates for blastic plasmacytoid dendritic cell neoplasm have been concerning, with the disease carrying a very low five-year survival rate overall. In the past, when treatment options were limited to conventional chemotherapy, the median overall survival was approximately one to one and a half years.^[7]

For patients who underwent allogeneic hematopoietic stem cell transplantation, outcomes have shown improvement compared to chemotherapy alone. A single-center study of individuals who received transplants showed a two-year survival rate of 65% and a five-year survival rate of 40%. For those who were in first complete remission at the time of transplant, the results were even better, with five-year progression-free survival and overall survival rates reaching 80%.^[13]

Another multicenter study examining patients in first complete remission who underwent allogeneic transplantation showed a three-year overall survival rate of 74%. These figures demonstrate that for carefully selected patients who can undergo transplantation while their disease is in remission, there is a meaningful chance of achieving longer-term survival.^[13]

It’s important to understand that survival statistics represent averages from groups of patients studied in the past and may not reflect individual outcomes. Additionally, newer treatments, particularly targeted therapies such as tagraxofusp-erzs (a medication that targets CD123 on cancer cells), are changing the treatment landscape. These advances may improve survival rates over time, though long-term data on newer therapies is still being collected.^[13]

Every person’s situation is unique, and factors such as age, overall health, how the disease responds to initial treatment, and access to specialized care all influence individual outcomes. While the overall statistics may seem discouraging, it’s crucial to remember that some patients do achieve long-term remission or cure, particularly those who respond well to treatment and undergo transplantation. Additionally, ongoing research continues to identify new therapeutic approaches that may offer hope for better outcomes in the future.

#1 Clinical Trials Search in Europe